Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform

Key Facts

CAMBRIDGE, Mass.--()--Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced it has raised $370 Million in a Series B financing to advance the development of its novel drug generation platform.
We are pioneering the field of Generative Biology – a revolutionary approach to drug development that allows us to program novel protein therapeutics capable of performing almost any desired biological function,” said Mike Nally, Chief Executive Officer, Generate Biomedicines and CEO-Partner, Flagship Pioneering.
Rather than only looking for opportunities from what’s observable in the lab, Generate Biomedicines is creating therapeutic opportunities by identifying specific biological processes involved in disease that can be modulated with a wide range of protein modalities—from short peptides to complex antibodies, enzymes, and cytokines.
About Generate Biomedicines Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered biomedicines platform with the potential to generate new drugs on demand across a wide range of biologic modalities—from short peptides to complex antibodies, enzymes, cytokines, and yet to be described protein compositions.